Effects of long‐term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis
Authors:
- Edward H. GianniniEGEdward H. Giannini
- Norman T. IlowiteNINorman T. Ilowite
- Pediatric Rheumatology Collaborative Study GroupPGPediatric Rheumatology Collaborative Study Group
- 29 October 2010
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 62 (11) , 3259-3264
Abstract
Objective: To evaluate the effects of long‐term etanercept treatment, with or without methotrexate, on growth in children with selected categories of juvenile idiopathic arthritis (JIA).Methods: We conducted a 3‐year, open‐label, nonrandomized registry of 594 patients with polyarticular or systemic JIA treated with etanercept only, etanercept plus methotrexate, or methotrexate only. Height, weight, and body mass index (BMI) were assessed at baseline and at years 1, 2, and 3, using percentiles derived from US Centers for Disease Control and Prevention standardized growth charts.Results: Statistically significant increases in the mean height percentiles from baseline were observed in etanercept‐treated patients at year 3 (4.8 percentile points) and in patients treated with etanercept plus methotrexate at years 1, 2, and 3 (2.4, 3.3, and 5.6 percentile points, respectively). Statistically significant increases from baseline in the mean weight percentiles were observed at years 1, 2, and 3 in both the etanercept group (7.4, 10.0, and 13.0 percentile points) and the etanercept‐plus‐methotrexate group (2.9, 6.9, and 8.4 percentile points, respectively). Statistically significant increases from baseline in the mean BMI percentiles were observed in both the etanercept group (range 9.6–13.8 percentile points) and the etanercept‐plus‐methotrexate group (range 2.1–5.2 percentile points). The mean height, weight, and BMI percentiles did not change significantly in patients in the methotrexate‐only group.Conclusion: Etanercept treatment, with or without methotrexate, may contribute to the restoration of normal growth in children with JIA.Keywords
This publication has 10 references indexed in Scilit:
- Long‐term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritisArthritis & Rheumatism, 2009
- Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA RegistryAnnals of the Rheumatic Diseases, 2009
- Disease control and health‐related quality of life in juvenile idiopathic arthritisArthritis Care & Research, 2009
- Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritisAnnals of the Rheumatic Diseases, 2006
- Juvenile idiopathic arthritisAutoimmunity Reviews, 2006
- Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset typeArthritis & Rheumatism, 2003
- Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcomeRheumatology, 2002
- Etanercept in Children with Polyarticular Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Growth Retardation in Non-steroid Treated Juvenile Rheumatoid ArthritisScandinavian Journal of Rheumatology, 1997
- Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.Archives of Disease in Childhood, 1976